HOME SITEMAP FEEDBACK ARCHIVES MEDIA KIT SUBSCRIBE
Search:     Help
Advertisement
 
Home > Bio Business
Stem Cells The Holy Grail
Narayan Kulkarni
Tuesday, October 14, 2008
New Page 1

Stem Cells
The Holy Grail

Patients across the world are holding on to the tenuous thread of life by the hope stem cell therapy provides while the research itself is facing challenges of all kinds-scientific, political, legal and ethical. In this special report BioSpectrum captures what the business leaders are doing to commercialize the research and sustain until we reach the goalpost.

Penetration of Stem Cell Therapy in APAC Region

  • Singapore has the highest penetration for stem cell therapy, achieving almost 25% penetration rate by 2010.

  • Both Thailand & Taiwan have similar penetration rates achieving overall penetration of almost 4% by 2010.

  • Malaysia on the other hand has a relatively lower penetration rate at 1.2% by 2010.

  • India offers penetration of 5% by 2010 largely accounted by stem cell therapies derived out of cord blood banking. It has
    three international players already creating a headstart.

  • In the APAC regions, Singapore has the highest penetration with a CAGR of almost 66% for market penetration over the next five years. Malaysia leads second with a CAGR of 33%. Taiwan & Thailand lead on the basis of sheer numbers, but would have a comparatively lower demand trajectory due to restrictive healthcare policies. Source: Stempeutics

 

Narayan Kulkarni & Sanjeev Jain


Page(s)   1  


Current Issue
Current Issue

Advertisement



Read Testimonials
EDITORIAL
BIONEWS

Advertisement










Google Web biospectrumindia.com
Other CyberMedia websites
Dataquest |  Voice&Data |  PCQuest |  Living Digital |  DQ Channels |  The DQweek
CIOL |  IDC India |  CyberMedia Careers |  CyberMedia Events |  CyberMedia Digital
Cyber Astro |  CyberMedia India |  Global Services |  BioSpectrum Asia

About BioSpectrum | Feedback | Contact Us

 
Copyright © CyberMedia All rights reserved. 
Reproduction in whole or in part in any form or medium without express written permission is prohibited. 
Usage of this web site is subject to terms and conditions.

Broken links? Problem with site? Send email to webmaster@cybermedia.co.in